At Retina Associates of Southern California, we are dedicated to being at the forefront of newly developed treatment plans and medications for various conditions involving the retina. Over the past 14 years, Dr. Hani Salehi-Had has participated in more than 30 clinical trials for a variety of retina conditions, including diabetic retinopathy, tractional retinal detachment, exudative and non-exudative age-related macular degeneration, diabetic macular edema, vitreomacular hole and vitreomacular traction. Our dedicated team of clinical research professionals has allowed our patients to gain access to promising new therapeutics that are not yet available to the general public.
List of Current Clinical Trials:
- Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS) Learn More
- A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety ofConbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (PANDA) Learn More
- A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KINGFISHER) Learn More
- Xplore: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration (XPLORE) Learn More
- A Multicenter, Randomized, Double-Masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 weeks Compared to Afliberecept 2 mg q4 Weeks in Patients with Neovascular Age-Related Macular Degeneration (nAMD) with Persistent Retinal Fluid (MERLIN) Learn More
- A 64 week, two-arm, randomized, double masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6mg compared to aflibercept 2mg in a treat-to-control regimen in patients with Neovascular Age-Related Macular Degeneration (TALON) Learn More
- A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (Apellis OAKS) Learn More
- DRCR Retina Network Protocol AF: This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in participants with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. Learn More
- DRCR network Protocol AJ: The proteomics of vitreous samples from eyes with full-thickness macular holes undergoing vitrectomy and from control eyes undergoing vitrectomy (eyes with no retinal disease) with vitreous opacities causing floaters or dislocated intraocular lens will be analyzed in two phases: the discovery phase will determine which proteins are up- and down-regulated, and the validation phase will target the most promising proteins found in the discovery phase. Learn More
If you would like more information regarding any of our clinical trials or believe you might be a good candidate, please contact us by calling (657)-227-9496.